TG Therapeutics (NASDAQ:TGTX) Receives Buy Rating from HC Wainwright

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $55.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 59.79% from the stock’s current price.

Several other equities research analysts have also recently weighed in on TGTX. JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. StockNews.com lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 31st. Finally, The Goldman Sachs Group boosted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Trading Up 14.4 %

NASDAQ:TGTX opened at $34.42 on Tuesday. The firm has a market capitalization of $5.36 billion, a P/E ratio of -344.17 and a beta of 2.30. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company has a fifty day moving average of $30.79 and a 200 day moving average of $28.24. TG Therapeutics has a 52 week low of $12.93 and a 52 week high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. The firm had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, research analysts predict that TG Therapeutics will post 0.08 earnings per share for the current year.

Insider Activity

In related news, CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the transaction, the chief financial officer now directly owns 670,632 shares of the company’s stock, valued at $20,313,443.28. This trade represents a 1.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Private Advisor Group LLC grew its stake in shares of TG Therapeutics by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after buying an additional 542 shares during the last quarter. New York State Teachers Retirement System purchased a new stake in shares of TG Therapeutics in the third quarter worth $1,004,000. Amalgamated Bank increased its holdings in shares of TG Therapeutics by 712.0% during the third quarter. Amalgamated Bank now owns 39,528 shares of the biopharmaceutical company’s stock valued at $925,000 after acquiring an additional 34,660 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its stake in TG Therapeutics by 33.7% in the 3rd quarter. Los Angeles Capital Management LLC now owns 123,401 shares of the biopharmaceutical company’s stock worth $2,886,000 after purchasing an additional 31,124 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.